Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar User Fee Collections Rise, But Little Spent On Program Costs

Executive Summary

FDA attributes large carryover balance to uncertainty in knowing when it has reached statutory funding threshold that triggers access to fees.

You may also be interested in...



US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017

For the first time since the biosimilar user fee program began, FDA spent more in fees than it collected, and more than it spent in appropriated funds.

US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017

For the first time since the biosimilar user fee program began, FDA spent more in fees than it collected, and more than it spent in appropriated funds.

The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees

Agency will substantially reduce amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal 2022; carryover generic drug and biosimilar fees will go toward hiring term-limited employees and building capacity, but a technical issue will keep FDA from accessing $79m in PDUFA fees.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS057595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel